72135-36-5

Basic information

• Product Name: 4-BROMO-2-METHOXYBENZOIC ACID
• Synonyms: 4-BROMO-2-METHOXYBENZOIC ACID;2-Methoxy-4-bromobenzoic acid;5-Bromo-2-carboxyanisole;Benzoic acid,4-broMo-2-Methoxy-
• CAS NO: 72135-36-5
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Acids & Esters;Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds
• Mol File: 72135-36-5.mol
• Article Data: 13

Chemical Properties

• Melting Point: 155-159°C
• Boiling Point: 318.077 °C at 760 mmHg
• Flash Point: 146.168 °C
• Appearance: /
• Density: 1.625 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Room temperature.
• PKA: 3.86±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-2-METHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-METHOXYBENZOIC ACID(72135-36-5)
• EPA Substance Registry System: 4-BROMO-2-METHOXYBENZOIC ACID(72135-36-5)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 72135-36-5(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow liquid

InChI:InChI=1/C8H7BrO3/c1-12-7-4-5(9)2-3-6(7)8(10)11/h2-4H,1H3,(H,10,11)

Upstream product

• 89368-12-7 1-[4-bromo-2-(methyloxy)phenyl]ethanone 
• 43192-33-2 4-bromo-2-methoxybenzaldehyde 
• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 
• 330793-38-9 4-bromo-2-methoxybenzonitrile 
• 1666-28-0 4-bromosalicylic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Downstream Products

• 1666-28-0 4-bromosalicylic acid 
• 89075-38-7 2-(4-Bromo-2-methoxy-phenyl)-3H-imidazo[4,5-c]pyridine; hydrochloride 
• 5213-16-1 4-bromo-2-methoxybenzoyl chloride 
• 89384-00-9 2-(4-bromo-2-methoxyphenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 72135-35-4 2-methoxy-4-bromo-5-chlorosulphonyl-benzoic acid 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 
• 1231191-67-5 N'-acetyl-4-bromo-2-methoxybenzohydrazide 
• 1419221-33-2 2-methoxy-N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1464157-34-3 4-bromo-2-methoxyphenyl-(4-tert-butoxycarbonylpiperazine-1-yl)methanone 
• 1464154-12-8 (2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1464150-74-0 4-(6-(3-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyrazin-3-yl)benzonitrile 
• 1092564-35-6 (2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(morpholino)methanone 
• 1464154-88-8 (4-(imidazo[1,2-b]pyridazin-6-yl)-2-methoxyphenyl)(morpholino)methanone 
• 1464154-89-9 (4-(3-iodoimidazo[1,2-b]pyridazin-6-yl)-2-methoxyphenyl)(morpholino)methanone 

Relevant articles and documents

Design, synthesis, and preliminary biological evaluation of 3′,4′,5′-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

According to the pharmacophore combination principle, a set of new 3′,4′,5′-trimethoxy flavonoid salicylate derivatives were designed, synthesized, and evaluated for biological activity. The cytotoxicity evaluation revealed that compound 10v exhibited higher potency than 5-Fu against HCT-116 cells. Preliminary biological activity studies showed that compound 10v could inhibit the colony formation and migration of HCT-116 cells. Besides, the Hoechst 33258 staining assay and flow cytometry revealed that treatment with compound 10v induced the apoptosis of HCT-116 cells in a concentration-dependent manner, while it had no effect on their cell cycle. The WB analysis suggested that HIF-1α, tubulin, HK-2, and PFK might be the potential pharmacophore targets of compound 10v. Tubulin was a potential drug target for compound 10v, which was explained by analyzing the crystal structure of compound 10v complexed with tubulin. These results indicated that compound 10v might be a promising anti-tumor agent candidate, deserving further optimization and evaluation.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

CYCLIC AMIDE DERIVATIVE

Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C6-10 arylene, etc.; R1a, R1b and R1c each independently is a hydrogen atom, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, etc.; R2 is an optionally substituted C6-10 aryl group, an optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C7-16 aralkyl group, etc.; m is 0, etc.; n is an integer of 0 to 2.)